Q1 Earnings Forecast for UTHR Issued By HC Wainwright

United Therapeutics Corporation (NASDAQ:UTHR) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for United Therapeutics in a report issued on Thursday, February 26th. HC Wainwright analyst A. Fein expects that the biotechnology company will earn $6.93 per share for the quarter. HC Wainwright has a “Buy” rating and a $600.00 price target on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. HC Wainwright also issued estimates for United Therapeutics’ Q2 2026 earnings at $6.84 EPS, FY2027 earnings at $36.46 EPS and FY2030 earnings at $51.17 EPS.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the business earned $6.19 EPS.

A number of other research firms also recently issued reports on UTHR. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a report on Thursday. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. UBS Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Finally, Bank of America reissued a “neutral” rating on shares of United Therapeutics in a research report on Wednesday. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $533.55.

United Therapeutics Price Performance

Shares of UTHR opened at $503.90 on Monday. United Therapeutics has a one year low of $266.98 and a one year high of $537.19. The business has a fifty day moving average of $484.38 and a 200 day moving average of $447.90. The firm has a market capitalization of $22.09 billion, a P/E ratio of 18.06, a PEG ratio of 1.78 and a beta of 0.84.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently modified their holdings of the stock. Mishpacha Holdings Corp purchased a new position in United Therapeutics during the fourth quarter valued at $487,000. Seven Fleet Capital Management LP purchased a new position in shares of United Therapeutics during the fourth quarter valued at about $633,000. DGS Capital Management LLC grew its position in shares of United Therapeutics by 20.3% during the fourth quarter. DGS Capital Management LLC now owns 841 shares of the biotechnology company’s stock valued at $410,000 after purchasing an additional 142 shares in the last quarter. Kera Capital Partners Inc. bought a new stake in shares of United Therapeutics in the fourth quarter worth about $208,000. Finally, Dorsey Wright & Associates purchased a new stake in shares of United Therapeutics in the fourth quarter worth about $2,499,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 21,000 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the completion of the sale, the chief financial officer owned 8,142 shares in the company, valued at approximately $3,896,761.20. This trade represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $478.58, for a total value of $10,768,050.00. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 360,454 shares of company stock valued at $174,796,043. Corporate insiders own 10.30% of the company’s stock.

Key United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.